Ramadan Fasting in Secondary Adrenal Insufficiency Patients

Fasting, Intermittent Clinical Trial

Official title:

Ramadan Fasting in Secondary Adrenal Insufficiency Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05827965
• Other study ID #: 1/2023
• Status: Active, not recruiting
• Phase: N/A
• Start date: March 1, 2023
• Est. completion date: March 1, 2024

Study information

• Verified date: February 2024
• Source: Hopital La Rabta
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Intermittent Ramadan fasting was associated with a risk of complications in patients with adrenal insufficiency. A risk stratification with recommendations (lifestyle and drug adjustment) for fasting in these patients has been recently published. So, this prospective interventional study was carried out to evaluated these recommendations. Patients with secondary adrenal insufficiency and willing to fast Ramadan were included. Before Ramadan, patients underwent a clinical examination and were educated for lifestyle measures and the schedule of glucocorticoid replacement therapy was adjusted. The occurrence of complications and the number of fasted days during the month of Ramadan 2023 were reported and compared with those of Ramadan 2022.

Description:

Intermittent fasting during the month of Ramadan is one of the five pillars of Islam and a sacred ritual for Muslims. Patients with chronic diseases seek advice from their physician and insist on fasting. A former study showed that 76.7% of adrenal insufficiency patients were exempted from fasting and 50.5% of them fasted against the advice of their physician. Few studies have assessed the risk of complications in adrenal insufficiency patients. The most frequently reported complications were asthenia (88.5%), signs suggestive of dehydration (49.2%), intense thirst (32.8%), and signs of hypoglycaemia (18%). Hypoglycaemia was detected by 24 hour-continuous glucose monitoring in 10% of fasting patients with secondary adrenal insufficiency (SAI). These complications were more frequent in patients with insufficient knowledge of the disease. A literature review was published 2021 and a risk stratification of patients with adrenal insufficiency and recommendations for patient education and therapeutic adjustment were proposed. However, no study has evaluated the effect of these measures on Ramadan fasting in SAI.

The objectives were to:

1. compare the number of fasted days and the prevalence of complications during Ramadan fasting before (2022) and after therapeutic education and treatment adjustment (2023) in patients with SAI.

2. determine the factors associated with complications during Ramadan fasting in SAI.

Methods:

Before the month of Ramadan 2023, patients meeting the inclusion criteria were enrolled. All patients signed a written informed consent.

During the first visit, the following data were recorded:

• gender, age, medical and surgical history, current treatments, medication schedule, the 2022 fast (number of fasted days, complications (type, days, time, break of the fast for a complication)).

• weight, height, lying and standing blood pressure.

• Some data were taken from the medical file: other affected pituitary axes, etiology of the SAI, results of the insulin hypoglycaemia test if performed (baseline cortisol, peak level, peak time, area under the curve), plasma creatinine.

Subsequently, patient education (the particularities of the disease, the risks and lifestyle measures) and therapeutic adjustments were performed according to the recommendations published by Chihaoui et al in Endocrine, 2021.

Throughout the month of Ramadan 2023, patients filled in forms indicating for the fasted days: dinner time, shour time, sleep time, unusual physical activity, treatment schedule, occurrence of complications: type, time, break of the fast for a complication.

Throughout the study, regular telephone contact with one of the investigators was performed for any additional information, advice or therapeutic adjustment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 63
• Est. completion date: March 1, 2024
• Est. primary completion date: December 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients aged over 18 years

• Secondary adrenal insufficiency patients

• Substituted with glucocorticoids for more than one year.

• Willing to fast during the month of Ramadan 2023

Exclusion Criteria:

• cardiac insufficiency,

• respiratory insufficiency,

• hepatic insufficiency,

• renal insufficiency (creatinine clearance < 60 ml/min/1.73m2),

• advanced neoplasia,

• undernutrition,

• diabetes insipidus,

• diabetes mellitus,

• neuro-psychiatric disease,

• infectious disease

• chronic inflammatory disease,

• hyperthyroidism,

• uncontrolled hypothyroidism,

• alcoholism,

• diuretic intake,

• glucocorticoid treatment for purposes other than substitution,

• treatment with enzyme inducers,

• pregnancy,

• breastfeeding

• consent withdrawn

• study discontinuation.

Related Conditions & MeSH terms

• Adrenal Insufficiency
• Fasting, Intermittent
• Neoplasm Metastasis
• Secondary Adrenal Insufficiency

Intervention

Behavioral:
• education and drug adjustement
education of the patients (lifestyle) and adjustement of glucocorticoid replacement schedule

Locations

Country	Name	City	State
Tunisia	University Hospital La Rabta	Tunis

Sponsors (1)

Lead Sponsor	Collaborator
Hopital La Rabta

Country where clinical trial is conducted

Tunisia, 

References & Publications (5)

Chihaoui M, Chaker F, Yazidi M, Grira W, Ben Amor Z, Rejeb O, Slimane H. Ramadan fasting in patients with adrenal insufficiency. Endocrine. 2017 Jan;55(1):289-295. doi: 10.1007/s12020-016-1186-0. Epub 2016 Nov 23. — View Citation

Chihaoui M, Grira W, Bettaieb J, Yazidi M, Chaker F, Rejeb O, Oueslati I, Feki M, Kaabachi N, Slimane H. The risk for hypoglycemia during Ramadan fasting in patients with adrenal insufficiency. Nutrition. 2018 Jan;45:99-103. doi: 10.1016/j.nut.2017.07.014. Epub 2017 Aug 3. — View Citation

Chihaoui M, Mimita W, Oueslati I, Rejeb O, Ben Amor Z, Grira W, Yazidi M, Chaker F. Prednisolone or hydrocortisone replacement in patients with corticotrope deficiency fasting during Ramadan result in similar risks of complications and quality of life: a randomized double-blind controlled trial. Endocrine. 2020 Jan;67(1):155-160. doi: 10.1007/s12020-019-02082-w. Epub 2019 Sep 24. — View Citation

Chihaoui M, Yazidi M, Oueslati I, Khessairi N, Chaker F. Intermittent fasting in adrenal insufficiency patients: a review and guidelines for practice. Endocrine. 2021 Oct;74(1):11-19. doi: 10.1007/s12020-021-02804-z. Epub 2021 Jul 2. — View Citation

Hussain S, Hussain S, Mohammed R, Meeran K, Ghouri N. Fasting with adrenal insufficiency: Practical guidance for healthcare professionals managing patients on steroids during Ramadan. Clin Endocrinol (Oxf). 2020 Aug;93(2):87-96. doi: 10.1111/cen.14250. Epub 2020 Jun 15. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of fasted days	change in the number of fasted days	one month
Primary	prevalence of complications	change in the prevalece of complications	one month